Effect of Thalidomide in Covid 19 pneumonia

Phase 3

• Conditions: Pneumonia caused by Coronavirus 2019, COVID19.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200428047232N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

18-75 year old men and 50-75 year old women admitted in hospital
Percentage of oxygen saturation at the time of admission: 89-85% (provided it is modified with Nazal auxiliary oxygen to more or equal to 90%) or oxygen saturation percentage of 90-93% and the number of breaths per minute more or equal to 30
Clinical manifestations associated with COVID-19 pneumonia with positive PCR test or HR-CT scan

Exclusion Criteria

Previous Chronic lung disease
Multi-organ failure at admission

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to reach clinical recovery. Timepoint: Daily visit in the hospital every 8 hours by the physician. Method of measurement: Pulse oximetery device.

Secondary Outcome Measures

Name	Time	Method
28 days survival rate. Timepoint: Weekly up to 4 weeks from the time of hospitalization to 4 weeks after discharge. Method of measurement: Telephone call.